Norharmane potentiated anxiolytic- and antidepressant-like responses induced by imipramine and citalopram: an isobologram analysis.

Journal

Behavioural pharmacology

ISSN: 1473-5849

Titre abrégé: Behav Pharmacol

Pays: England

ID NLM: 9013016

Informations de publication

Date de publication:
04 Oct 2024

Historique:

medline: 3 10 2024

pubmed: 3 10 2024

entrez: 3 10 2024

Statut: aheadofprint

Résumé

β-carboline compounds display a therapeutic property for treating depression and anxiety behaviors. Imipramine and citalopram play an important role in the modulation of anxiety and depression behaviors. We investigated the effects of norharmane, imipramine, and citalopram on anxiety- and depression-like effects and their interactions. Elevated plus maze and forced swimming test were used for the assessment of anxiety- and depression-like behaviors in male mice. The results revealed that intraperitoneal (i.p.) administration of norharmane (10 mg/kg) increased percentage of open arm time (%OAT) in the elevated plus maze test and decreased immobility time in the forced swimming test, proposing anxiolytic- and antidepressant-like effects. Injection of imipramine (5 mg/kg; i.p.) enhanced %OAT and decreased immobility time, suggesting anxiolytic- and antidepressant-like effects. Moreover, norharmane potentiated the anxiolytic- and antidepressant-like responses induced by imipramine by increasing %OAT and decreasing immobility time. The results revealed additive anxiolytic- and antidepressant-like effects between norharmane and imipramine in mice. Alone, the administration of citalopram (5 mg/kg; i.p.) enhanced %OAT and reduced immobility time, causing anxiolytic- and antidepressant-like effects. When citalopram and norharmane were coinjected, norharmane augmented the anxiolytic- and antidepressant-like effects induced by citalopram by increasing %OAT and reducing immobility time. These results indicated additive anxiolytic- and antidepressant-like effects between norharmane and antidepressant drugs such as imipramine and citalopram on the modulation of anxiety and depression processes in mice.

Identifiants

DOI: 10.1097/FBP.0000000000000794 PMID: 39361265

pubmed: 39361265

doi: 10.1097/FBP.0000000000000794

pii: 00008877-990000000-00101

doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Informations de copyright

Références

Abu Ghazaleh H, Lalies MD, Nutt DJ, Hudson AL (2015). The modulatory action of harmane on serotonergic neurotransmission in rat brain [Research Support, Non-U.S. Gov’t]. Brain Res 1597:57–64.

Adell A, Biggs TA, Myers RD (1996). Action of harman (1-methyl-β-carboline) on the brain: body temperature and in vivo efflux of 5-HT from hippocampus of the rat. Neuropharmacology 35:1101–1107.

Alijanpour S, Khakpai F, Ebrahimi-Ghiri M, Zarrindast M-R (2019). Co-administration of the low dose of orexin and nitrergic antagonists induces an antidepressant-like effect in mice. Biomed Pharmacother 109:589–594.

Bahi A (2017). Environmental enrichment reduces chronic psychosocial stress-induced anxiety and ethanol-related behaviors in mice. Prog Neuropsychopharmacol Biol Psychiatry 77:65–74.

Baum SS, Hill R, Rommelspacher H (1996). Harman-induced changes of extracellular concentrations of neurotransmitters in the nucleus accumbens of rats. Eur J Pharmacol 314:75–82.

Cacabelos R, Torrellas C (2015). Pharmacogenomics of antidepressants. HSOA J Psych Dep Anx 1:1–42.

Carhart-Harris R, Nutt D (2017). Serotonin and brain function: a tale of two receptors. J Psychopharmacol 31:1091–1120.

Costa-Nunes JP, Cline BH, Araújo-Correia M, Valença A, Markova N, Dolgov O, et al. (2015). Animal models of depression and drug delivery with food as an effective dosing method: evidences from studies with celecoxib and dicholine succinate. Biomed Res Int 2015:596126.

Dixon WJ (1991). Staircase bioassay: The up-and-down method. Neurosci Biobehav Rev 15:47–50.

Dorow R, Horowski R, Paschelke G, Amin M, Braestrup C (1983). Severe anxiety induced by FG 7142, a β-carboline ligand for benzodiazepine receptors. Lancet 322:98–99.

Egan RJ, Bergner CL, Hart PC, Cachat JM, Canavello PR, Elegante MF, et al. (2009). Understanding behavioral and physiological phenotypes of stress and anxiety in zebrafish [Research Support, Non-U.S. Gov’t]. Behav Brain Res 205:38–44.

Farzin D, Mansouri N (2006). Antidepressant-like effect of harmane and other β-carbolines in the mouse forced swim test. Eur Neuropsychopharmacol 16:324–328.

Feighner JP, Overo K (1999). Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression. J Clin Psychiatry 60:824–830.

Fekkes D (1996). Norharman and anxiety disorders. Acta Neuropsychiatr 8:93–95.

Ferraz CAA, de Oliveira Júnior RG, Picot L, da Silva Almeida JRG, Nunes XP (2019). Pre-clinical investigations of β-carboline alkaloids as antidepressant agents: a systematic review. Fitoterapia 137:104196.

Glennon RA, Dukat M, Grella B, Hong S, Costantino L, Teitler M, et al. (2000). Binding of β-carbolines and related agents at serotonin (5-HT2 and 5-HT1A), dopamine (D2) and benzodiazepine receptors. Drug Alcohol Depend 60:121–132.

Grella B, Teitler M, Smith C, Herrick-Davis K, Glennon RA (2003). Binding of β-carbolines at 5-HT2 serotonin receptors. Bioorg Med Chem Lett 13:4421–4425.

Grillon C, Levenson J, Pine DS (2007). A single dose of the selective serotonin reuptake inhibitor citalopram exacerbates anxiety in humans: a fear-potentiated startle study. Neuropsychopharmacology 32:225–231.

Grillon C, Chavis C, Covington MF, Pine DS (2009). Two-week treatment with the selective serotonin reuptake inhibitor citalopram reduces contextual anxiety but not cued fear in healthy volunteers: a fear-potentiated startle study. Neuropsychopharmacology 34:964–971.

Heshmati P (2014). An overview of cognitive aspects of s-carbolines. Arch Adv Biosci 5:99–104.

Huang R, Pei L, Liu QJ, Chen S, Dou H, Shu G, et al. (2019). Isobologram analysis: a comprehensive review of methodology and current research. Front Pharmacol 10:1222.

Jaka O, Iturria I, van der Toorn M, Hurtado de Mendoza J, Latino DARS, Alzualde A, et al. (2021). Effects of natural monoamine oxidase inhibitors on anxiety-like behavior in zebrafish. Front Pharmacol 12:669370.

Keller MB (2000). Citalopram therapy for depression: a review of 10 years of European experience and data from US clinical trials [Comparative Study Research Support, Non-U.S. Gov’t Review]. J Clin Psychiatry 61:896–908.

Kellner M, Porseryd T, Hallgren S, Porsch-Hällström I, Hansen SH, Olsén KH (2016). Waterborne citalopram has anxiolytic effects and increases locomotor activity in the three-spine stickleback (Gasterosteus aculeatus). Aquat Toxicol 173:19–28.

Khakpai F, Ramezanikhah M, Valizadegan F, Zarrindast M-R (2021). Synergistic effect between imipramine and citicoline upon induction of analgesic and antidepressant effects in mice. Neurosci Lett 760:136095.

Kocsis JH, Frances AJ, Voss C, Mann JJ, Mason BJ, Sweeney J (1988). Imipramine treatment for chronic depression. Arch Gen Psychiatry 45:253–257.

Kuhn W, Müller T, Gerlach M, Sofic E, Fuchs G, Heye N, et al. (1996). Depression in Parkinson’s disease: biogenic amines in CSF of ‘de novo’ patients. J Neural Transm (Vienna) 103:1441–1445.

Lipman RS, Covi L, Rickels K, McNair DM, Downing R, Kahn RJ, et al. (1986). Imipramine and chlordiazepoxide in depressive and anxiety disorders: I. Efficacy in depressed outpatients. Arch Gen Psychiatry 43:68–77.

Marcusson JO, Ross SB (1990). Binding of some antidepressants to the 5-hydroxytryptamine transporter in brain and platelets. Psychopharmacology (Berl) 102:145–155.

Matto V, Allikmets L (1999). Acute and chronic citalopram treatment differently modulates rat exploratory behavior in the exploration box test: no evidence for increased anxiety or changes in the [3H] raclopride binding. Pharmacology 58:59–69.

Moloudizargari M, Mikaili P, Aghajanshakeri S, Asghari MH, Shayegh J (2013). Pharmacological and therapeutic effects of Peganum harmala and its main alkaloids. Pharmacogn Rev 7:199–212.

Mombereau C, Gur TL, Onksen J, Blendy JA (2010). Differential effects of acute and repeated citalopram in mouse models of anxiety and depression [Research Support, N.I.H., Extramural]. Int J Neuropsychopharmacol 13:321–334.

Moura DJ, Rorig C, Vieira DL, Henriques JAP, Roesler R, Saffi J, Boeira JM (2006). Effects of beta-carboline alkaloids on the object recognition task in mice [Research Support, Non-U.S. Gov’t]. Life Sci 79:2099–2104.

Nejati S, Khakpai F, Zarrindast M-R (2020). Synergistic effect between citalopram and citicoline on anxiolytic effect in non-sensitized and morphine-sensitized mice: an isobologram analysis. Brain Res 1734:146701.

Pahkla R, Rägo L, Callaway JJ, Airaksinen MM (1997). Binding of pinoline on the 5-hydroxytryptamine transporter: competitive interaction with [3H] citalopram. Pharmacol Toxicol 80:122–126.

Pellow S, File SE (1986). Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat. Pharmacol Biochem Behav 24:525–529.

Petersen EN, Jensen LH (1984). Proconflict effect of benzodiazepine receptor inverse agonists and other inhibitors of GABA function. Eur J Pharmacol 103:91–97.

Pieroni A, Muenz H, Akbulut M, Başer KHC, Durmuşkahya C (2005). Traditional phytotherapy and trans-cultural pharmacy among Turkish migrants living in Cologne, Germany. J Ethnopharmacol 102:69–88.

Quesseveur G, Nguyen HT, Gardier AM, Guiard BP (2012). 5-HT2 ligands in the treatment of anxiety and depression [Research Support, Non-U.S. Gov’t Review]. Expert Opin Investig Drugs 21:1701–1725.

Ramirez K, Sheridan JF (2016). Antidepressant imipramine diminishes stress-induced inflammation in the periphery and central nervous system and related anxiety-and depressive-like behaviors. Brain Behav Immun 57:293–303.

Reus GZ, Stringari RB, de Souza B, Petronilho F, Dal-Pizzol F, Hallak JE, et al. (2010). Harmine and imipramine promote antioxidant activities in prefrontal cortex and hippocampus. Oxid Med Cell Longevity 3:325–331.

Réus GZ, Stringari RB, Gonçalves CL, Scaini G, Carvalho-Silva M, Jeremias GC, et al. (2012). Administration of harmine and imipramine alters creatine kinase and mitochondrial respiratory chain activities in the rat brain. Depress Res Treat 2012:1–7.

Rickels K, Downing R, Schweizer E, Hassman H (1993). Antidepressants for the treatment of generalized anxiety disorder: a placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry 50:884–895.

Rommelspacher H, Schmidt LG, May T (1991). Plasma norharman (β‐carboline) levels are elevated in chronic alcoholics. Alcohol Clin Exp Res 15:553–559.

Rommelspacher H, Meier-Henco M, Smolka M, Kloft C (2002). The levels of norharman are high enough after smoking to affect monoamineoxidase B in platelets. Eur J Pharmacol 441:115–125.

Rook Y, Schmidtke K-U, Gaube F, Schepmann D, Wünsch B, Heilmann J, et al. (2010). Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents. J Med Chem 53:3611–3617.

Russell JM, Koran LM, Rush J, Hirschfeld RM, Harrison W, Friedman ES, et al. (2001). Effect of concurrent anxiety on response to sertraline and imipramine in patients with chronic depression. Depress Anxiety 13:18–27.

Schneier F. R. (2003). Citalopram treatment of social anxiety disorder with comorbid major depression [Clinical TrialResearch Support, Non-U.S. Gov’t]. Depress Anxiety 17:191–196.

Schouten MJ, Bruinvels J (1986). Endogenously formed norharman (beta-carboline) in platelet rich plasma obtained from porphyric rats. Pharmacol Biochem Behav 24:1219–1223.

Simões LR, Netto S, Generoso JS, Ceretta RA, Valim RF, Dominguini D, et al. (2019). Imipramine treatment reverses depressive-and anxiety-like behaviors, normalize adrenocorticotropic hormone, and reduces interleukin-1β in the brain of rats subjected to experimental periapical lesion. Pharmacol Rep 71:24–31.

Simon NM, Sharma SG, Worthington JJ, Marzol PC, Pollack MH (2001). Citalopram for social phobia: a clinical case series. Prog Neuropsychopharmacol Biol Psychiatry 25:1469–1474.

Stohler R, Hug I, Knoll B, Mohler B, Ladewig D (1996). Initial results with withdrawal treatments of male and female participants in the diversified Janus opiate prescription project in Basel. Praxis 85:1537–1541.

Talhout R, Opperhuizen A, van Amsterdam JGC (2007). Role of acetaldehyde in tobacco smoke addiction [Review]. Eur Neuropsychopharmacol 17:627–636.

Varia I, Rauscher F (2002). Treatment of generalized anxiety disorder with citalopram [Clinical Trial Research Support, Non-U.S. Gov’t]. Int Clin Psychopharmacol 17:103–107.

Varia IM, Cloutier CA, Doraiswamy PM (2002). Treatment of social anxiety disorder with citalopram. Prog Neuropsychopharmacol Biol Psychiatry 26:205–208.

Wong W, Wallace MS (2014). Determination of the effective dose of pregabalin on human experimental pain using the sequential up-down method. J Pain 15:25–31.

Zarrindast MR, Sahebgharani M (2002). Effect of alpha-adrenoceptor agonists and antagonists on imipramine-induced antinociception in the rat formalin test. Pharmacology 64:201–207.

Zendehdel M (2013). The role of 5-HT 2A and 5-HT 2C receptors on harmaline-induced eating behavior in 24-h food-deprived broiler cockerels. Iran J Vet Res 14:94–99.